Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2025-01-09 Report Publication Anno…
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
Report Publication Announcement Classification · 1% confidence The document is a short press release titled "THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS". It explicitly states that the 'letter to shareholders' has been published and provides a direct link to download it. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of another report with a link, it should be classified as a Report Publication Announcement (RPA). The document is only 3449 characters long and its primary function is to announce the availability of the 'Letter to Shareholders'.
2025-01-09 English
THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES
Report Publication Announcement Classification · 1% confidence The document is a very short announcement (3849 characters) titled "THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES" (Theranexus announces the publication of its letter to shareholders). It explicitly states that the letter is published and provides links to download or view it. According to Rule #2 (The "MENU VS MEAL" Rule), when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA). The specific document being announced is a 'lettre aux actionnaires' (shareholder letter), which is a type of investor communication, but the filing itself is the announcement of its release.
2025-01-09 French
THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON
Capital/Financing Update Classification · 1% confidence The document is titled "THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON" and details the company's current cash balance (€1.5 M), expected short-term inflows (€4.8 M from licensing, grants, and bank reimbursements), and the resulting extension of the cash flow horizon to Q1 2026. It also mentions debt restructuring with banking partners. This content focuses on financial status, liquidity, and capital structure management, which aligns best with the 'Capital/Financing Update' category. While it discusses cash flow, it is not a formal Earnings Release (ER) or a comprehensive Interim Report (IR); rather, it is a specific announcement regarding financing and cash runway. Therefore, 'CAP' is the most appropriate classification.
2024-12-17 English
THERANEXUS FAIT UN POINT SUR SA POSITION DE TRÉSORERIE ET SON HORIZON DE FINANCEMENT
Capital/Financing Update Classification · 1% confidence The document is a press release dated December 17, 2024, titled "THERANEXUS FAIT UN POINT SUR SA POSITION DE TRÉSORERIE ET SON HORIZON DE FINANCEMENT" (Theranexus provides an update on its cash position and financing runway). It details the current cash balance (€1.5 M), expected near-term cash inflows (€3.3 M from a license agreement and Bpifrance, plus a small debt adjustment), and the resulting extended cash runway until Q1 2026. It also mentions debt restructuring with banks. This content focuses on financial status, liquidity, and financing activities, which aligns best with the 'Capital/Financing Update' category (CAP). It is not a full Annual Report (10-K), an Interim Report (IR), or a simple Earnings Release (ER) which usually focuses on P&L/Balance Sheet figures for a completed period. It is a specific update on financing and cash management.
2024-12-17 French
THERANEXUS ET EXELTIS (INSUD PHARMA) ANNONCENT UN ACCORD DE LICENCE POUR LA COMMERCIALISATION DU TX01 DE THERANEXUS DANS LE TRAITEMENT DE DEUX MALADIES NEUROLOGIQUES RARES
Capital/Financing Update Classification · 1% confidence The document announces a licensing and commercialization agreement between Theranexus and Exeltis (Insud Pharma) regarding a drug candidate (TX01) for rare neurological diseases. This involves financial terms (upfront payment, milestones, royalties) and exclusive rights transfer. This type of corporate action, specifically related to asset licensing, financing, or strategic partnerships that impact future revenue streams and operations, falls best under 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. However, given the focus on the financial structure of the deal (payments, royalties) and the strategic nature of securing commercialization rights, 'CAP' is the most appropriate fit among the provided options, as it relates to capital structure/funding strategy, even if it's not a direct equity raise. It is not an earnings release (ER), an interim report (IR), or a management discussion (MDA). It is a specific corporate transaction announcement.
2024-12-17 French
THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIALIZE THERANEXUS TX01 FOR TWO RARE NEUROLOGICAL DISORDERS
Capital/Financing Update Classification · 1% confidence The document announces a significant business event: a licensing agreement between two pharmaceutical companies, Theranexus and Exeltis (Insud Pharma), for commercializing a drug (TX01). This involves financial terms (upfront payment, milestones, royalties) and strategic partnership details. This type of announcement, detailing a major transaction or financing activity, aligns best with the 'Capital/Financing Update' category, as it involves a significant financial deal structuring the future revenue stream and development rights. While it is not a formal SEC filing like a 10-K, it is a material corporate event announcement. It is not an Earnings Release (ER), an Interim Report (IR), or a standard Regulatory Filing (RNS) which usually covers less specific operational news. The core subject is the structuring of a commercial deal, which fits best under CAP (Capital/Financing Update) or potentially TAR (M&A Activity), but since it is a licensing deal rather than a merger or takeover, CAP is more appropriate.
2024-12-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.